Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 16;20(1):765.
doi: 10.1186/s12879-020-05485-7.

A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine In Severe COvid-19 (PISCO) trial protocol

Sergio Fragoso-Saavedra  1   2 , David A Iruegas-Nunez  2   3 , Alejandro Quintero-Villegas  4 , H Benjamín García-González  4 , Isaac Nuñez  4 , Sergio L Carbajal-Morelos  4 , Belem M Audelo-Cruz  2 , Sarahi Arias-Martínez  2 , Yanink Caro-Vega  5 , Juan José Calva  5 , Verónica Luqueño-Martínez  5 , Alejandra González-Duarte  2 , Brenda Crabtree-Ramírez  5 , José C Crispín  6 , Juan Sierra-Madero  5 , Pablo F Belaunzarán-Zamudio  5   7 , Sergio I Valdés-Ferrer  8   9   10
Affiliations

A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine In Severe COvid-19 (PISCO) trial protocol

Sergio Fragoso-Saavedra et al. BMC Infect Dis. .

Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the causative agent of coronavirus disease 2019 (COVID-19), may lead to severe systemic inflammatory response, pulmonary damage, and even acute respiratory distress syndrome (ARDS). This in turn may result in respiratory failure and in death. Experimentally, acetylcholine (ACh) modulates the acute inflammatory response, a neuro-immune mechanism known as the inflammatory reflex. Recent clinical evidence suggest that electrical and chemical stimulation of the inflammatory reflex may reduce the burden of inflammation in chronic inflammatory diseases. Pyridostigmine (PDG), an ACh-esterase inhibitor (i-ACh-e), increases the half-life of endogenous ACh, therefore mimicking the inflammatory reflex. This clinical trial is aimed at evaluating if add-on of PDG leads to a decrease of invasive mechanical ventilation and death among patients with severe COVID-19.

Methods: A parallel-group, multicenter, randomized, double-blinded, placebo-controlled, phase 2/3 clinical trial to test the efficacy of pyridostigmine bromide 60 mg/day P.O. to reduce the need for invasive mechanical ventilation and mortality in hospitalized patients with severe COVID-19.

Discussion: This study will provide preliminary evidence of whether or not -by decreasing systemic inflammation- add-on PDG can improve clinical outcomes in patients with severe COVID-19.

Trial registration: ClinicalTrials.gov NCT04343963 (registered on April 14, 2020).

Keywords: ACh; COVID-19; Immunomodulation; Inflammatory reflex; Invasive mechanical ventilation; Mortality; Placebo-controlled trial; Pyridostigmine; SARS-Cov-2.

PubMed Disclaimer

Conflict of interest statement

Pablo F Belaunzarán-Zamudio is an Associated Editor for the HIV and co-infections section of BMC Infectious Diseases.

Figures

Fig. 1
Fig. 1
The PISCO trial (Pyridostigmine in Severe COVID-19) study design and schedule of follow-up visit
Fig. 2
Fig. 2
Protocol Activities. All timepoints are counted from enrollment (Baseline). Arrows indicate specific actions to be performed at each predefined timepoint. Patients who are discharged from hospital before day 14 are not required to return for blood sampling. Abbreviations: ABG: arterial blood gases; IL-6: interleukin 6
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5. - DOI - PMC - PubMed
    1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;6736:1–9. doi: 10.1016/S0140-6736(20)30566-3. - DOI - PMC - PubMed
    1. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46:846–848. doi: 10.1007/s00134-020-05991-x. - DOI - PMC - PubMed
    1. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;6736:19–20. doi: 10.1016/S0140-6736(20)30628-0. - DOI - PMC - PubMed
    1. Valdés-Ferrer SI. The challenges of long-term sepsis survivors: when surviving is just the beginning. Rev Investig Clin. 2014;66:439. - PubMed

Publication types

MeSH terms

Substances

Associated data

LinkOut - more resources